Chemokine receptor antagonism as a new therapy for multiple sclerosis

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.9, Iss.5, 2000-05, pp. : 1079-1097

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

By Amato Maria Pia

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2115-2126

Informa Healthcare

Access to resources Recommend Favorite

Advances in Antioxidative Therapy of Multiple Sclerosis

Current Medicinal Chemistry, Vol. 20, Iss. 37, 2013-11 ,pp. : 4720-4730

Bentham Science Publishers

Access to resources Recommend Favorite

Teriflunomide for oral therapy in multiple sclerosis

By Papadopoulou Athina Kappos Ludwig Sprenger Till

Expert Review of Clinical Pharmacology, Vol. 5, Iss. 6, 2012-11 ,pp. : 617-628

Informa Healthcare

Access to resources Recommend Favorite

Basic and escalation therapy of multiple sclerosis

PHARMAKON, Vol. 2, Iss. 6, 2014-11 ,pp. : 414-421

Govi-Verlag

Access to resources Recommend Favorite

Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis

Current Drug Targets. Inflammation & Allergy, Vol. 3, Iss. 3, 2004-01 ,pp. : 279-290

Bentham Science Publishers

Access to resources Recommend Favorite